All In Biotech

Drug Trial Radar · NCT07226999

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung Cancer

A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 550 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Dec 9, 2025

Primary completion

Jun 14, 2030

Study completion Mar 11, 2034

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to learn more about an investigational medicine called PF-08634404 when used alone or in combination with other anti-cancer medicines in adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread beyond the lung. PF-08634404 is designed to target two pathways involved in cancer growth and survival. The study will also evaluate combinations with chemotherapy and tarlatamab, an approved immunotherapy that helps the body's immune system recognize and attack small cell lung cancer cells. To join the study, participants must meet the following conditions: * 18 years of age or older. * Have extensive-stage small cell lung cancer confirmed by laboratory testing. * Have measurable disease on imaging scans. * Be in generally good physical condition and have adequate organ function. * For most study groups, have not received prior systemic treatment for extensive-stage small cell lung cancer, although participants who received a single cycle of chemotherapy for life-threatening disease-related symptoms are eligible. The study has two parts: Phase 2 Researchers will evaluate the safety, tolerability, and preliminary anti-cancer activity of PF-08634404. Participants may receive: * PF-08634404 plus chemotherapy, * PF-08634404 plus tarlatamab, or * PF-08634404 plus tarlatamab and chemotherapy. The results will help determine the recommended dose and treatment regimen for future study. Phase 3 Researchers will compare PF-08634404 plus chemotherapy with an approved treatment regimen consisting of atezolizumab plus chemotherapy. The goal is to determine whether PF-08634404 can improve outcomes such as overall survival.

Conditions

  • Small Cell Lung Cancer (SCLC)

Interventions

  • PF-08634404Drug

    Concentrate for solution for infusion

  • TarlatamabDrug

    Lyophilized powder intended for reconstitution and dilution for intravenous use

  • ChemotherapyDrug

    Injection for intravenous use

  • AtezolizumabDrug

    Injection for intravenous use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Number of participants with treatment-emergent adverse eventsTime frame: Up to 90 days after the last dose of treatment
  2. Phase 3: Overall Survival (OS)Time frame: Up to approximately 2 years after completion of study treatment of last study participant

Locations

85 sites in 10 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas · Recruiting

  • Highlands Oncology Group

    Rogers, Arkansas · Recruiting

  • Highlands Oncology Group

    Springdale, Arkansas · Recruiting

  • BRCR Coral Springs

    Coral Springs, Florida · Recruiting

  • BRCR Global - Coral Springs

    Coral Springs, Florida · Recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • BRCR Global - Tamarac

    Tamarac, Florida · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Texas Oncology - Northeast Texas

    Allen, Texas · Recruiting

  • Texas Oncology - DFW

    Arlington, Texas · Recruiting

  • Texas Oncology - DFW

    Arlington, Texas · Recruiting

  • Texas Oncology - Gulf Coast

    Beaumont, Texas · Recruiting

  • Texas Oncology - DFW

    Bedford, Texas · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • Texas Oncology - DFW

    Dallas, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Denison, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Denton, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Flower Mound, Texas · Recruiting

  • Texas Oncology - DFW

    Fort Worth, Texas · Recruiting

  • Texas Oncology - San Antonio

    Fredericksburg, Texas · Recruiting

  • Texas Oncology - DFW

    Grapevine, Texas · Recruiting

  • Texas Oncology - Gulf Coast

    Houston, Texas · Recruiting

  • Texas Oncology - Gulf Coast

    Houston, Texas · Recruiting

  • US Oncology Investigational Product Center (IPC)

    Irving, Texas · Recruiting

  • US Oncology Investigational Products Center (IPC)

    Irving, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Lewisville, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Longview, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    McKinney, Texas · Recruiting

  • Texas Oncology - San Antonio

    New Braunfels, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Palestine, Texas · Recruiting

  • Texas Oncology - Northeast Texas

    Paris, Texas · Recruiting

  • Texas Oncology - Gulf Coast

    Pearland, Texas · Recruiting

  • Texas Oncology - DFW

    Plano, Texas · Recruiting

  • Texas Oncology - DFW

    Plano, Texas · Recruiting

  • Texas Oncology - San Antonio

    San Antonio, Texas · Recruiting

  • Texas Oncology - San Antonio

    San Antonio, Texas · Recruiting

  • Texas Oncology - San Antonio

    San Antonio, Texas · Recruiting

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.